As COVID-19 treatments become more readily available, and additional oral and IV treatments come online, providers now have expanded access for prescribing therapies to patients. Previously, COVID-19 treatments were only available through a pharmacy outreach program, due to limited supply.
A “COVID-19 Outpatient Treatment Options with Guidance” Smart Set is now available in One Chart. This tool provides guidance and decision support for providers when placing an order for COVID-19 therapies. The required documentation items are also built in to satisfy the legal requirements for these therapies under the FDA’s Emergency Use Authorizations (EUA).
To determine which therapy is the best option for your patient, use this flow diagram for outpatients with COVID-19 symptoms and a positive test result. The one-sheet also includes information on which medical conditions and factors put a patient at high risk of COVID-19 progression. A PDF of this information is also available for download at the bottom of this article. A tips sheet will be posted on the Learning Home within One Chart in the upcoming days.
Paxlovid (nirmatrelvir with ritonavir) and Lagevrio (molnupiravir) are stocked at Pharmacy locations in the Durham Outpatient Center, Lauritzen Outpatient Center, Bellevue and the University of Nebraska – Lincoln Health Center. Infusion options are also available for open prescribing. Infusions are administered at the Nebraska Medicine Infusion Center at Werner Cancer Hospital and Bellevue Medical Center.
Providers may use this therapeutics locator to find treatment availability outside of Nebraska Medicine.
The Pharmacy team is committed to providing support as these workflows change. Pharmacists in our ambulatory care clinics and retail locations are available to assist with any questions on these therapies.
Beginning May 16, pharmacy outreach efforts to patients with a positive COVID-19 test will be discontinued. This will prevent duplicate contacts and ordering. The Pharmacy Outreach Team inbox will remain open for provider questions until the end of the month.
Since November 2020, more than 5,200 Nebraska Medicine patients have been contacted for COVID-19 therapy. More than 2,200 patients have received treatment.